Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04675333
Title ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ALX Oncology Inc.

head and neck squamous cell carcinoma


Carboplatin + Evorpacept + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Carboplatin + Fluorouracil + Pembrolizumab

Cisplatin + Evorpacept + Fluorouracil + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ESP | BEL

No variant requirements are available.